HC Wainwright Analysts Boost Earnings Estimates for AQST

Aquestive Therapeutics, Inc. (NASDAQ:AQST) – Research analysts at HC Wainwright boosted their Q3 2026 earnings per share estimates for Aquestive Therapeutics in a report issued on Monday, August 24th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.09) for the quarter, up from their prior estimate of ($0.13). HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Aquestive Therapeutics’ current full-year earnings is ($0.50) per share. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q4 2026 earnings at ($0.09) EPS, FY2026 earnings at ($0.43) EPS, Q1 2027 earnings at ($0.09) EPS, Q2 2027 earnings at ($0.10) EPS, Q4 2027 earnings at ($0.10) EPS and FY2027 earnings at ($0.39) EPS.

A number of other research analysts have also commented on AQST. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Aquestive Therapeutics in a report on Friday, July 17th. Wall Street Zen lowered shares of Aquestive Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $8.80.

Aquestive Therapeutics Price Performance

Shares of Aquestive Therapeutics stock opened at $5.08 on Wednesday. Aquestive Therapeutics has a 1 year low of $2.93 and a 1 year high of $7.55. The company has a market capitalization of $637.59 million, a price-to-earnings ratio of -7.82 and a beta of 1.49. The business has a fifty day simple moving average of $4.21 and a two-hundred day simple moving average of $4.14.

Aquestive Therapeutics (NASDAQ:AQST) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The firm had revenue of $13.82 million during the quarter, compared to the consensus estimate of $11.42 million.

Insiders Place Their Bets

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of the stock in a transaction that occurred on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the sale, the director owned 25,000 shares of the company’s stock, valued at approximately $125,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 6.81% of the company’s stock.

Institutional Investors Weigh In On Aquestive Therapeutics

Several large investors have recently modified their holdings of the company. NewEdge Advisors LLC bought a new position in Aquestive Therapeutics during the third quarter worth $28,000. BNP Paribas Financial Markets boosted its position in Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after acquiring an additional 4,134 shares during the last quarter. Modern Wealth Management LLC acquired a new stake in Aquestive Therapeutics during the 2nd quarter worth about $33,000. Elevation Point Wealth Partners LLC bought a new position in shares of Aquestive Therapeutics in the 1st quarter worth about $42,000. Finally, ADAR1 Capital Management LLC lifted its stake in shares of Aquestive Therapeutics by 103.9% in the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after purchasing an additional 264,000 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.

Key Aquestive Therapeutics News

Here are the key news stories impacting Aquestive Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its FY2026 EPS forecast to a loss of $0.43 from a loss of $0.51 and lifted its FY2027 estimate to a loss of $0.39 from a loss of $0.52. The revisions indicate expectations for narrower losses and improving profitability. HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics
• Positive Sentiment: The analyst also improved quarterly forecasts: Q3 2026 EPS was raised to a loss of $0.09 from $0.13, Q4 2026 to a loss of $0.09 from $0.15, Q1 2027 to a loss of $0.09 from $0.15, and Q2 2027 to a loss of $0.10 from $0.15. The Q4 2027 estimate increased to a loss of $0.10 from $0.11.
• Positive Sentiment: HC Wainwright’s $10 target represents approximately 96.9% potential upside from the referenced $5.08 price, reinforcing the firm’s bullish view. Benzinga analyst-rating report
• Positive Sentiment: A recent report noted that AQST shares increased 5.02%, reflecting continued investor interest in the company and its outlook. Why Aquestive Therapeutics Stock Is Up 5.02%

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.